Berlin-chemie Ag

Oncoethix Gmbh

Debiopharm International, S.a.

Fondazione Per L'istituto Oncologico Di Ricerca (ior)

Medimmune Limited

Adc Therapeutics Sa

Universidade De Évora

Francesco Bertoni

Mario Bigioni

Monica Binaschi

Giuseppe Merlino

Andrea Pellacani

Cecilia Simonelli

Maria Eugenia Riveiro

Eric Raymond

Angela Romanelli

Francesca Zammarchi

Anthony Burke

Eugenio Gaudio

Natalina Pazzi

Matilde Guala

Callum Sloss

Natalia Busto Vazquez

Paola Bonetti

Carolina Silva Marques

The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.

Pharmaceutical combinations comprising an anti-LY75 antibody

The compounds of formula (I) where the group &#x2014;R may represent &#x2550;O or &#x2014;H, are new anti-proliferative agents with remarkable anti-tumour effects in-vivo, showing in particular a wide spectrum of activities in respect of lymphomas of different origin.

Compounds with enhanced anti-tumor effects

Methods for identifying and treating patients having cancer who are likely to respond to treatment with an anti-CD37 immunoconjugate (e.g., IMGN529) are provided.

Methods for improving anti-CD37 immunoconjugate therapy

A method of treating lymphoma in a mammal comprises the step of: administering to a patient a pharmaceutical acceptable amount of a compound being a thienotriazolodiazepine compound of the Formula (1) wherein Ris alkyl having a carbon number of 1-4, Ris a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, Ris a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; &#x2014;NR&#x2014;(CH)&#x2014;Rwherein Ris a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and Ris phenyl or pyridyl optionally substituted by a halogen atom; or &#x2014;NR&#x2014;CO&#x2014;(CH)&#x2014;Rwherein R is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and Ris phenyl or pyridyl optionally substituted by a halogen atom, and Ris &#x2014;(CH)&#x2014;CO&#x2014;NH&#x2014;Rwherein a is an integer of 1-4, and Ris alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or &#x2014;(CH)&#x2014;COORwherein b is an integer of 1-4, and Ris alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof. The lymphoma to be treated is diffuse large B-cell lymphom (DLBCL) specifically selected from activated B-cell DLBCL (ABC-DLBCL) and germinal B-cell DLBCL (GBC-DLBCL). 

Methods of treating lymphoma using thienotriazolodiazepine compounds

A method of treating non-small cell lung cancer and/or small cell lung cancer in a mammal comprises the step of administering to a patient a pharmaceutical acceptable amount of a compound being a thienotriazolodiazepine compound of the Formula (1). 

Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds

Growing community of inventors

Bellinzona, Switzerland

Francesco Bertoni